The evaluation of Copy Number Variants in an unselected population of patients with Inherited Cardiac Conditions: The INTERACTION Study

Clicks: 1
ID: 317476
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #73 of 83 articles by views in EP Europace

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
BACKGROUND AND AIMS: The current diagnostic approach to inherited cardiac conditions (ICCs) is primarily focused on the analysis of single-nucleotide variants (SNVs) and small insertions/deletions (InDels). However, as recommended for other inherited diseases, the analysis of Copy Number Variants (CNVs) should be equally considered. In cardiology, the diagnostic contribution of CNVs remains insufficiently studied, with limited evidence and no standardized recommendations for analytical workflows.This study aims to assess the prevalence of pathogenic CNVs in an Italian multicenter cohort of ICC patients, providing recommendations for integrating CNV analysis into routine genetic testing. METHODS: A total of 203 ICC probands with prior negative or inconclusive results for SNVs and InDels testing were included. The tertiary bioinformatic analysis was performed by eVai enGenome software, and putative CNVs were validated by Multiplex Ligation-dependent Probe Amplification (MLPA) assays. RESULTS: MLPA confirmed only one of the five initially suspected CNVs, identifying a deletion in MYBPC3 gene classified as pathogenic according to ACMG/AMP guidelines. This result confirmed a limited diagnostic yield of 0,50%. Considering the substantial costs, time constraints, and specialized expertise required, we propose a strategy to prioritize selected ICC patients for CNV analysis. CONCLUSIONS: Evidence from this real-world cohort suggests the incorporation of CNV analysis as a second-tier test in patients with ICC and specific clinical or molecular indications.
Reference Key
openalex_W7164938869 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors G Corona, Simona Mellone, Magliozzi Monia, Maria Gnazzo, Martina Manzoni, Fusco Carmela, Silvia Morlino, Italia Loddo, Floriana Barbera, Alioto Luigi, Paganini Stefania, Cucugliato Luisa, Andrea Faggiano, Andrioletti Valentina, Rossana Mineri, Girolami Francesca, Ivan Limongelli, Giordano Mara, Valeria Novelli
Journal EP Europace
Year 2026
DOI
10.1093/europace/euag150
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.